Screener
West Pharmaceutical Services WST Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by West Pharmaceutical Services in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The source filing: West Pharmaceutical Services’s 10-Q, filed July 23, 2026.
- Filed
- Jul 23, 2026, 4:15 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000105770-26-000099
| (in millions, except per share data) | June 30,2026 | December 31,2025 |
|---|---|---|
| Income taxes payable | 64.7 | 28.1 |
| Operating lease liabilities | 20.9 | 22.7 |
| Accrued commissions, rebates and royalties | 34.0 | 39.2 |
| Other current liabilities | 171.1 | 175.3 |
| Total current liabilities | 640.5 | 654.9 |
| Long-term debt | 202.9 | 202.8 |
| Deferred income taxes | 22.4 | 23.0 |
| Pension and other postretirement benefits | 28.3 | 29.0 |
Item 1. FINANCIAL STATEMENTS (UNAUDITED)
FAQ
- What is West Pharmaceutical Services's accrued expenses?
- West Pharmaceutical Services (WST) reported accrued expenses of $171.1M in Q2 2026.
- How has West Pharmaceutical Services's accrued expenses changed year-over-year?
- West Pharmaceutical Services's accrued expenses decreased by 23.2% year-over-year, from $222.8M to $171.1M.
- What is the long-term trend for West Pharmaceutical Services's accrued expenses?
- Over 5 years (2020 to 2025), West Pharmaceutical Services's accrued expenses has grown at a 4.1% compound annual growth rate (CAGR), from $143.6M to $175.3M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about West Pharmaceutical Services's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude